Amneal Pharmaceuticals, Inc.
AMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001723128
In the last 90 days, Amneal Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 3 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $2.91B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $7.22M in total
- 3
- 13F holdersQ2 2026, −4 vs. previous quarter
- 311
- 13F valueReported value at the end of Q2 2026
- $2.91B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AMRX, Q2 2026
No superinvestor reported holding AMRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Amneal Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 (view filing)4:29 PM ET | Aug 13 | 1 day | Kiely JohnDirector | SSaleClass A Common Stock | −50.0K | $17.64 | −$882.0K | −19.2%210.3K after | |
| Aug 13, 2026 (view filing)4:22 PM ET | Aug 12 | 1 day | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −146.4K | $17.51 | −$2.56M | −36.6%253.4K after | |
| Aug 13, 2026 (view filing)4:21 PM ET | Aug 11-12 | 2 days | Daly Jason B.EVP, Chief Legal Officer | SSaleClass A Common Stock | −216.6K | $17.41 | −$3.77M | −86.0%35.2K after | 2 lots |
| May 12, 2026 (view filing) | May 11 | 1 day | Autor Deborah M.Director | SSaleClass A Common Stock | −34.8K | $12.94 | −$450.6K | −27.1%93.7K after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Nark Ted CDirector | SSaleClass A Common Stock | −50.0K | $11.72 | −$586.0K | −14.7%291.0K after | |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −131.9K | $11.92 | −$1.57M | −47.4%146.4K after | |
| Aug 28, 2025 (view filing) | Aug 27 | 1 day | Kiely JohnDirector | SSaleClass A Common Stock | −32.0K | $9.23 | −$295.4K | −12.4%225.4K after | |
| Aug 25, 2025 (view filing) | Aug 22-25 | 3 days | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −120.8K | $9.65 | −$1.17M | −45.2%146.4K after | 2 lots |
| Aug 22, 2025 (view filing) | Aug 20 | 2 days | Boyer Andrew SExecutive Vice President | SSaleClass A Common Stock | −279.2K | $9.38 | −$2.62M | −64.7%152.4K after | |
| Aug 15, 2025 (view filing) | Aug 14 | 1 day | Shah NikitaExecutive Vice President | SSaleClass A Common Stock | −71.7K | $9.29 | −$666.0K | −21.2%267.2K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Amneal Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 26,562,093 | $459.8M | 0.01% | +2,042,901+8.3% | Added |
| TPG GP A, LLC | 12,328,767 | $213.4M | 4.27% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 12,137,727 | $210.1M | 0.01% | +812,794+7.2% | Added |
| Rubric Capital Management LP | 10,168,660 | $176.0M | 1.61% | −868,929−7.9% | Reduced |
| Vanguard Capital Management LLC | 7,710,126 | $133.5M | 0.00% | +125,092+1.6% | Added |
| State Street Corp | 7,356,977 | $127.3M | 0.00% | +562,275+8.3% | Added |
| Dimensional Fund Advisors LP | 5,794,263 | $100.3M | 0.02% | +103,677+1.8% | Added |
| Geode Capital Management, LLC | 5,139,449 | $89.0M | 0.00% | +593,401+13.1% | Added |
| Assenagon Asset Management S.A. | 4,891,098 | $84.7M | 0.05% | +1,823,737+59.5% | Added |
| Nantahala Capital Management, LLC | 4,537,502 | $78.5M | 2.38% | +1,693,394+59.5% | Added |